ECG studies with astemizole.
1 Six healthy volunteers took part in a 2-week haemodynamic safety study of astemizole. 2 They were given 30 mg daily (3 X 10 mg tablets) for the first 3 days and 10 mg daily for the next 12 consecutive days. 3 Heart rate, blood pressure, ECG and systolic time intervals at rest were measured before the start and five times during the day. 4 No changes were observed in any of the parameters measured. The configuration of the ECG was not influenced. 5 Serum concentrations of astemizole plus hydroxylated metabolites measured at the end of the study were 16 times lower than those detected in a patient overdosing on 200 mg astemizole.
D000328:Adult; D016589:Astemizole; D001562:Benzimidazoles / Q000097:blood / Q000494:pharmacology*; D004562:Electrocardiography; D005260:Female; D006439:Hemodynamics / Q000187:drug effects; D006635:Histamine H2 Antagonists / Q000097:blood / Q000494:pharmacology*; D006801:Humans; D008297:Male
D001562:Benzimidazoles; D006635:Histamine H2 Antagonists; D016589:Astemizole